Gilead Sciences GILD
NASDAQ GILD
$146.12 +2.68 (+1.87%)
At close: Aug 21, 2026 · 4:00 PM EDT

Gilead Sciences (GILD) Amortizatization of Intangibles (2009 - 2026)

Gilead Sciences' (GILD) quarterly Amortizatization of Intangibles came in at $596.0 million in Q1 2026, down 0.5% YoY from $599.0 million in Q1 2025, and little changed on a QoQ basis from $597.0 million in Q4 2025.

Gilead Sciences (GILD) Amortizatization of Intangibles (2009 - 2026) Analysis & Trends

Gilead Sciences (GILD) has 18 years of Amortizatization of Intangibles data on file, last reported at $596.0 million in Q1 2026.

  • Quarterly Amortizatization of Intangibles fell 0.5% year-over-year to $596.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 billion (changed 0.08% YoY) and the FY2025 annual result came in at $2.4 billion, changed 0.17% from the prior year.
  • Amortizatization of Intangibles held at $596.0 million in Q1 2026, from $597.0 million in the prior quarter.
  • In the past five years, Amortizatization of Intangibles ranged from a high of $599.0 million in Q1 2025 to a low of $445.0 million in Q1 2022.
  • A 5-year average of $558.3 million and a median of $596.0 million in 2024 frame the typical range for Amortizatization of Intangibles.
  • Annual changes were most pronounced in 2023 — Amortizatization of Intangibles soared 34.38% — and 2026, when it dropped 0.5%.
  • Tracing GILD's Amortizatization of Intangibles over 5 years: stood at $445.0 million in 2022, then jumped by 34.16% to $597.0 million in 2023, then increased by 0.17% to $598.0 million in 2024, then dropped by 0.17% to $597.0 million in 2025, then slipped by 0.17% to $596.0 million in 2026.
  • The last three Amortizatization of Intangibles figures came in at $596.0 million (Q1 2026), $597.0 million (Q4 2025), and $596.0 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Amortizatization of Intangibles (Qtr)
1 Johnson & Johnson 652.20 Bn 631.44 Bn 17.26 Bn -
2 AbbVie 469.51 Bn 462.94 Bn 12.70 Bn -
3 Merck 376.81 Bn 369.67 Bn 12.21 Bn 984.00 Mn
4 Novartis Ag 303.04 Bn 295.35 Bn 11.24 Bn -
5 Astrazeneca 257.61 Bn 252.71 Bn 12.86 Bn -
6 Amgen 237.37 Bn 223.38 Bn 7.24 Bn -
7 Gilead Sciences 181.73 Bn 178.55 Bn 6.22 Bn 600.00 Mn
8 Pfizer 159.66 Bn 147.96 Bn 10.94 Bn -
9 Gsk 106.24 Bn 102.07 Bn 8.24 Bn -
10 Sanofi 55.07 Bn 47.69 Bn 10.79 Bn -

Historic Data

Download Data
DateValue
Jun 30, 2026 600.00 Mn
Jun 30, 2026 600.00 Mn
Mar 31, 2026 596.00 Mn
Mar 31, 2026 596.00 Mn
Dec 31, 2025 597.00 Mn
Dec 31, 2025 597.00 Mn
Sep 30, 2025 596.00 Mn
Sep 30, 2025 596.00 Mn
Jun 30, 2025 598.00 Mn
Jun 30, 2025 598.00 Mn
Mar 31, 2025 599.00 Mn
Mar 31, 2025 599.00 Mn
Dec 31, 2024 598.00 Mn
Dec 31, 2024 598.00 Mn
Sep 30, 2024 596.00 Mn
Sep 30, 2024 596.00 Mn
Jun 30, 2024 596.00 Mn
Jun 30, 2024 596.00 Mn
Mar 31, 2024 596.00 Mn
Mar 31, 2024 596.00 Mn